

Day : Sunday
Date: 1/13/2002
Time: 20:26:18


PALM INTRANET

Docket	Reg. New	Reg. Amended	Spl.	Spl. Amended	Rejected	Counte
			New			

Special New Cases

(WARNING: Data Security and Confidentiality Restriction Apply)

Name : **JAGOE,**
DONNA

Examiner Number :
77149

Group Art Unit : **1614**

Special New Cases Oldest New S.N. :
: 5 09688020 Age: 01

Oldest Effective S.N. :
09946623 Age:02

Appln #	Filing Date	Status	Loc	Chg to Loc	Class	Subclass	Type	Title
<u>09/814394</u>	03/21/2001	30	16C3	16X1	514	340.000	CON	COMPO METHO CARDIC CONDIT
<u>09/940723</u>	08/27/2001	30	16L1	16X1	424	049.000	CON	DENTAL ANTI-H COMPO METHO
<u>09/946623</u>	09/06/2001	30	16C3	16X1	514	300.000	CON	COMBIN IN THE CARDIC DISORI
<u>09/991694</u>	11/26/2001	30	16C3	-	514	206.000	DIV	COMPO COMPR CRYSTA STABLE CEPHAL PROCES PREPAR
<u>09/995022</u>	11/26/2001	30	16L1	16X1	514	001.000	DIV	METHO ENHAN HEALIN



ORIGINAL ARTICLE

Volume 338:217-220 January 22, 1998 Number 4

A Comparison of Botulinum Toxin and Saline for the Treatment of Chronic Anal Fissure

Giorgio Maria, M.D., Emanuele Cassetta, M.D., Daniele Gui, M.D., Giuseppe Brisinda, M.D., Anna Rita Bentivoglio, M.D., and Alberto Albanese, M.D.

ABSTRACT

Background Chronic anal fissure is a tear in the lower half of the anal canal that is maintained by contraction of the internal anal sphincter. Sphincterotomy, the most widely used treatment, is a surgical procedure that permanently weakens the internal sphincter and may lead to anal deformity and incontinence.

Methods We conducted a double-blind, placebo-controlled study of **botulinum** toxin for the treatment of chronic anal fissure in 30 consecutive symptomatic adults. All the patients received two injections (total volume, 0.4 ml) into the internal anal sphincter; the treated group (15 patients) received 20 U of **botulinum** toxin A, and the control group (15 patients) received saline. Success was defined as healing of the fissure (formation of a scar), and symptomatic improvement was defined as the presence of a persistent fissure without symptoms.

Results After two months, 11 patients in the treated group and 2 in the control group had healed fissures ($P = 0.003$); 13 in the treated group and 4 in the control group had symptomatic

ARTICLE

- ▶ [Return to Search Result](#)
- ▶ [Table of Contents](#)
- ▶ [Abstract of this article](#)
- ▶ [PDF of this article](#)
- ▶ [Related Letters to the Editor](#)
- Related editorials in the Journal:
 - ▶ [Madoff, R. D.](#)
- ▶ [Find Similar Articles in the Journal](#)
- ▶ [Journal Watch Summary](#)
- ▶ [Journal Watch Summary](#)
- ▶ [Articles citing this article](#)

SERVICES

- ▶ [Add to Personal Archive](#)
- ▶ [Download to Citation Manager](#)
- ▶ [Alert me when this](#)

relief (P = 0.003). The maximal voluntary pressures were similar to those at base line in both groups, and the resting anal pressure was reduced by 25 percent in the treated group but not in the control group.

Three patients in the control group later underwent sphincterotomy, and 10 received **botulinum**-toxin injections (20 U). Of the latter, seven had healed fissures after two months; the other three left the study and underwent surgery. Four patients in the treated group were later re-treated (with 25 U of **botulinum** toxin); all had healed fissures after two months. One patient in the control group had temporary flatus incontinence after treatment with **botulinum** toxin. No relapses occurred during an average of 16 months of follow-up.

Conclusions Local infiltration of **botulinum** toxin into the internal anal sphincter is an effective treatment for chronic anal fissure.

article is cited
MEDLINE
► Related Articles in Medline
Articles in Medline by Author:
► Maria, G.
► Albanese, A.
► Medline Citation
COLLECTIONS
► Gastroenterology Related Chapters
► at Harrison's Online

Anal fissure, first recognized as a clinical entity in 1934,¹ is a split extending from the anal verge toward the dentate line. Ninety percent of primary fissures are posterior; the pathogenesis is thought to be related to severe constipation or to straining at stool, since the hard fecal bolus may crack the anal canal.² A chronic idiopathic fissure can be clearly recognized as a well-circumscribed ulcer,³ with symptoms persistently present for more than two months. A characteristic skin tag may develop distally, while proximally a hypertrophy of anal papilla may be observed.² The fissure is maintained by contraction of the internal anal sphincter.

Chronic anal fissure is believed to be common and underdiagnosed. An epidemiologic survey conducted in 1994 among proctologic clinics in Italy showed that 10 percent of 15,161 consecutive outpatients were affected by anal fissure.⁴ Surgical sphincterotomy is currently performed to provide symptomatic relief and healing. However, the procedure permanently weakens the internal sphincter and may be associated with such permanent complications as anal deformity and incontinence. Two therapeutic approaches — chemical denervation with **botulinum** toxin and topical application of nitroglycerin ointments — have been proposed

as noninvasive alternatives.^{5,6} In an open-label study, we observed that chronic anal fissure may be effectively treated with local infiltration of **botulinum** toxin.⁶ Therefore, we conducted a double-blind, placebo-controlled study of **botulinum** toxin for treatment of chronic anal fissure.

Methods

Study Population

Consecutive symptomatic adults with chronic idiopathic anal fissure were enrolled. Patients with acute fissures, those with anal fissures of various causes (i.e., hemorrhoids, fistula in ano, inflammatory bowel diseases), and those who had previously undergone anal surgical procedures were excluded. The study was approved by the ethics committee of the Catholic University of Rome; all the patients provided written informed consent.

Study Design

This was a randomized, double-blind, placebo-controlled study. All the patients underwent a pretreatment evaluation consisting of a clinical assessment, anoscopy, and anorectal manometry. Eligible patients were randomly assigned to one of the two study groups according to a computer-generated list. The treating physician did not know the randomization code. In each patient, anal manometry was performed at rest and after maximal voluntary contraction, and the results were compared with the normal range for our laboratory.⁷ Each of the 30 participants received 0.4 ml of solution divided into two injections of equal volume. The internal anal sphincter was easily palpated and injected with a 27-gauge needle; the solution was placed close to the fissure on each side. No sedation or local anesthesia was used. Patients in the control group received just saline solution; patients in the treated group received 20 U of **botulinum** toxin A (Botox, Allergan, Irvine, Calif.; 50 U per milliliter).

Follow-Up

The patients were advised to eat food with a high fiber content and received a prescription for laxatives. No patient was treated with topical **anesthetics** before or during the study. All the patients were evaluated by clinical examination, anoscopy, and anal manometry, regardless of their treatment and outcome, one and two months after the injections. If the fissure persisted at the two-month evaluation, the examiner (who remained blinded to the patient's treatment assignment) could decide to re-treat a patient ("rescue" treatment). The re-treated patients always received **botulinum** toxin; patients in the control group received 20 U, and patients in the treated group received 25 U. Re-treated patients were then evaluated with the same protocol one month and two months after re-treatment. At each visit, the patients could choose to be treated with anal sphincterotomy or to drop out of the study. All the patients were followed clinically until September 1996.

Statistical Analysis

The outcome of each group was evaluated clinically (by checking for a healing scar or fissure) and by comparing the strength of the internal and external anal sphincters, as measured by anal manometry. Success was defined as healing of the fissure, and symptomatic improvement was defined as the persistence of an anal fissure without symptoms.

The time course of pressure variations was analyzed with Student's t-test. The clinical outcomes of the two groups were compared by means of Fisher's exact test.⁸ All P values were two-tailed. A P value of less than 0.05 was considered to indicate statistical significance.

Results

From June 1994 to December 1995, 30 consecutive outpatients were enrolled; 15 received **botulinum** toxin, and 15 received placebo. All the patients reported severe typical pain after defecating, and each had a posterior anal fissure with a large sentinel tag of skin and the exposure of fibers of the internal anal sphincter. The two groups were similar with regard to age, sex, the duration of symptoms, and the resting anal

pressure at base line ([Table 1](#)). The maximal voluntary pressure at base line was lower in the treated group ($P < 0.001$).

<p>View this table: [in this window] [in a new window]</p>	<p>Table 1. Base-Line Characteristics of the 30 Patients with Chronic Anal Fissure.</p>
---	--

At one month, two patients in the control group and eight in the treated group had healed fissures ($P = 0.05$). Symptomatic relief was reported by 4 patients in the control group and 13 in the treated group ($P = 0.003$).

At two months, 2 patients in the control group and 11 in the treated group had healed fissures ($P = 0.003$), and 4 patients in the control group and 13 in the treated group had symptomatic relief ($P = 0.003$). During the first two months, three patients in the control group dropped out of the study to undergo sphincterotomy.

Control Group

At one month, post-defecatory pain was no longer present in three patients in the control group (including the two with healing scars) and was reduced in one. Nocturnal pain was no longer present in one of the two patients who had previously reported it. As compared with base-line values, the resting anal pressure and the maximal voluntary pressure were unchanged ([Table 2](#)).

<p>View this table: [in this window] [in a new window]</p>	<p>Table 2. Anal Pressures in Patients in the Control Group.</p>
---	---

At two months, an additional patient reported a reduction in post-defecatory pain. Another no longer had nocturnal pain but still had

pain after defecation. The resting anal pressure and the maximal voluntary pressure were similar to base-line and one-month values. Of the 13 patients with persistent fissures, 3 refused rescue treatment and underwent sphincterotomy. The remaining 10, all of whom reported having pain after defecation, received 20 U of **botulinum** toxin each.

At three months (one month after rescue treatment), four patients had healing scars. Two of the six patients with persistent fissures no longer had pain after defecation. The other four had reduced pain; three dropped out of the study and underwent sphincterotomy. The mean maximal voluntary pressures in these 10 patients were similar before and after the rescue treatment. The mean (\pm SD) resting anal pressure at three months was 85 ± 7 mm Hg, 20.7 percent lower than at two months in these patients.

At four months (two months after the rescue treatment), the remaining three patients had healing scars; none had pain after defecation. The mean resting anal pressure in these three patients was 67 ± 7 mm Hg — 37.5 percent lower than their pretreatment values and 43.6 percent lower than their values at two months, but similar to their values at one month. The maximal voluntary pressure was unchanged in these patients.

Treated Group

At one month, eight patients in the treated group had healing scars with symptomatic relief. Of the seven patients with persistent fissures, post-defecatory pain was no longer present in one and was reduced in four. Nocturnal pain was no longer present in the two patients who had previously reported it. As compared with base-line values, the resting anal pressure was reduced by 27 percent; the maximal voluntary pressure was not significantly changed ([Table 3](#)).

View this table:
[\[in this window\]](#)
[\[in a new window\]](#)

Table 3. Anal Pressures in Patients in the Treated Group.

At two months, 11 patients had healing scars. One patient who had had a healing scar at one month now had a fissure. Post-defecatory pain was no longer present in 11 patients and was reduced in 2. Nocturnal pain was not reported by any patient in the treated group. The resting anal pressure was reduced by 25 percent as compared with base-line values and was similar to one-month values. The maximal voluntary pressure was similar to base-line and one-month values.

The four patients who still had fissures were re-treated with 25 U of **botulinum** toxin. At three months (one month after the second injection), two of these four patients had healing scars and no pain after defecation. The resting anal pressure and the maximal voluntary pressure in the four patients who received the rescue treatment were similar to the values at base line, one month, and two months.

At four months (two months after the rescue treatment), the remaining two patients also had healing scars, and their post-defecatory pain had resolved. The resting anal pressure and the maximal voluntary pressure in the re-treated patients remained similar to the values at base line, one month, and two months.

Follow-Up

One patient in the control group had flatus incontinence one month after the rescue treatment; this resolved after approximately one week. No other complications or side effects were reported.

Seven patients with healed fissures in the control group who had received rescue treatment were followed for an average of 18 ± 5 months (range, 10 to 24). There were no relapses. All the patients in the treated group were reevaluated periodically for an average of 16 ± 6 months (range, 7 to 26). There were no relapses.

Discussion

Anal fissure is currently treated with lateral internal sphincterotomy. This is effective in about 90 percent of cases and must be performed under general or local anesthesia.⁹ Despite concern about a higher rate of recurrence, good results are reported for outpatient sphincterotomy performed under local anesthesia.¹⁰ Surgery for anal fissure is associated with a number of complications, most of which are minimized by the judicious use of surgical techniques.¹¹ The most common is incontinence, which in 8 to 30 percent of patients is permanent.^{12,13} Recently, chronic fissures have been successfully treated with topical nitroglycerin ointment.⁵ Two to six weeks of treatment are required to heal 47 to 85 percent of patients.^{14,15} A significant reduction of spontaneous and post-defecatory pain was observed five minutes after an application. This treatment is thought to reduce anal pressure and improve local blood flow.¹⁶ The most common side effects are transient headache, occurring in the majority of patients, and anal burning; incontinence has not been reported.¹⁶ Tachyphylaxis after repeated applications has been observed.

Our study demonstrates that **botulinum** toxin can be used to treat chronic fissures. Fissures healed in all the patients in the treated group after one or two successive injections of **botulinum** toxin, as compared with 13 percent of the patients who received one injection of saline. The percentage of patients with healing was higher than in our previous open-label study,⁶ which showed that 60 percent of patients had healing after a single treatment with 15 U of **botulinum** toxin. The use of higher doses and the availability of a rescue treatment account for the higher success rate in this study. As in our previous study, manometry confirmed that the injected internal anal sphincter was weakened and that no significant diffusion of **botulinum** toxin to the external sphincter took place. By contrast, **botulinum** toxin injected into the external anal sphincter, which is also effective for treating fissures, has been shown to diffuse to the internal sphincter.¹⁷

The base-line maximal voluntary pressure was higher in the control

group than in the treated group. This difference may have reflected differences in the severity of pain and a prevalence of men (men have higher anal pressures)¹⁸ in the control group. This base-line imbalance did not affect the results, since the maximal voluntary pressure remained relatively unchanged in each group. Injections were performed in the internal anal sphincter, which controls the resting anal pressure, not the maximal voluntary pressure.

The injections were easily performed, were painless, and did not cause any local or systemic complications. The muscle weakening produced by **botulinum** toxin was transient.

Chronic anal fissures may be maintained by local ischemia.¹⁹ **Botulinum** toxin may induce healing by simply increasing local blood flow or by more complex mechanisms.^{20,21}

In summary, we found local infiltration of **botulinum** toxin into the internal anal sphincter to be a promising approach to the treatment of anal fissure, particularly if patients are at risk for incontinence. It is less expensive and easier to perform than surgical treatments and does not require anesthesia. A direct comparison of **botulinum** toxin and topical nitroglycerin ointment should be conducted.

Supported in part by a grant (96.02994.04) from the Consiglio Nazionale delle Ricerche.

Source Information

From the Istituto di Clinica Chirurgica (G.M., D.G., G.B.) and the Istituto di Neurologia (A.R.B., A.A.), Università Cattolica del Sacro Cuore, Rome; and Associazione Fatebenefratelli Ricerca-Istituto di Ricovero e Cura a Carattere Scientifico, Centro S. Giovanni di Dio, Fatebenefratelli, Brescia, Italy (E.C.).

Address reprint requests to Dr. Albanese at the Istituto di Neurologia, Università Cattolica, Largo Argostino Gemelli 8, I-00168 Rome, Italy.

References

1. Lockhart-Mummery JP. Diseases of the rectum and colon and their surgical treatment. Toronto: MacMillan, 1934.
2. Lund JN, Scholefield JH. Aetiology and treatment of anal fissure. Br J

- Surg 1996;83:1335-44.
3. Notaras MJ. Anal fissure and stenosis. Surg Clin North Am 1988;68:1427-1440.[\[Medline\]](#)
 4. Pescatori M, Interisano A. Annual report of the Italian coloproctology units. Tech Coloproctol 1995;3:29-30.
 5. Gorfine SR. Topical nitroglycerin therapy for anal fissures and ulcers. N Engl J Med 1995;333:1156-1157.[\[Full Text\]](#)
 6. Gui D, Cassetta E, Anastasio G, Bentivoglio AR, Maria G, Albanese A. **Botulinum** toxin for chronic anal fissure. Lancet 1994;344:1127-1128.[\[Medline\]](#)
 7. Pescatori M, Anastasio G, Pavesio R. The role of ano-rectal functional investigation in the diagnosis and treatment of faecal incontinence. Coloproctology 1989;11:120-4.
 8. Dixon WJ, Massey FJ Jr. Introduction to statistical analysis. 4th ed. New York: McGraw-Hill, 1983.
 9. Oh C, Divino CM, Steinhagen RM. Anal fissure: 20-year experience. Dis Colon Rectum 1995;38:378-382.[\[Medline\]](#)
 10. Gordon PH, Vasilevsky CA. Symposium on outpatient anorectal procedures: lateral internal sphincterotomy: rationale, technique and anesthesia. Can J Surg 1985;28:228-230.[\[Medline\]](#)
 11. Mazier WP. Hemorrhoids, fissures, and pruritus ani. Surg Clin North Am 1994;74:1277-1292.[\[Medline\]](#)
 12. Abcarian H, Lakshmanan S, Read DR, Roccaforte P. The role of internal sphincter in chronic anal fissure. Dis Colon Rectum 1982;25:525-528.[\[Medline\]](#)
 13. Pernikoff BJ, Eisenstat TE, Rubin RJ, Oliver GC, Salvati EP. Reappraisal of partial lateral internal sphincterotomy. Dis Colon Rectum 1994;37:1291-1295.[\[Medline\]](#)
 14. Lund JN, Armitage NC, Scholefield JH. Use of glyceryl trinitrate ointment in the treatment of anal fissure. Br J Surg 1996;83:776-777.[\[Medline\]](#)
 15. Watson SJ, Kamm MA, Nicholls RJ, Phillips RKS. Topical glyceryl trinitrate in the treatment of chronic anal fissure. Br J Surg 1996;83:771-775.[\[Medline\]](#)
 16. Simons AJ, Beart RW Jr. Glyceryl trinitrate for anal fissure. Lancet 1996;348:491-492.[\[Medline\]](#)
 17. Jost WH, Schimrigk K. Therapy of anal fissure using botulin toxin. Dis Colon Rectum 1994;37:1321-1324.[\[Medline\]](#)
 18. Pedersen IK, Christiansen J. A study of the physiological variation in anal manometry. Br J Surg 1989;76:69-70.[\[Medline\]](#)
 19. Schouten WR, Briel JW, Auwerda JJA, De Graaf EJR. Ischaemic nature

of anal fissure. *Br J Surg* 1996;83:63-65. [\[Medline\]](#)

20. Albanese A, Bentivoglio AR, Cassetta E, Viggiano A, Maria G, Gui D. The use of **botulinum** toxin in the alimentary tract. *Aliment Pharmacol Ther* 1995;9:599-604. [\[Medline\]](#)

21. Ashton AC, Dolly JO. Characterization of the inhibitory action of **botulinum** neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes. *J Neurochem* 1988;50:1808-1816. [\[Abstract\]](#)

Related Letters:

Treatment of Chronic Anal Fissure

Pérez-Miranda M., Jiménez J. M., Maria G., Gui D., Brisinda G., Madoff R. D.

[\[Full Text \]](#)

N Engl J Med 1998; 338:1698-1699, Jun 4, 1998.

Correspondence

This article has been cited by other articles:

PHILLIPS, R K S, PHILLIPS, R K S (1998).

Botulinum toxin promoted healing and relieved symptoms of chronic anal fissure. • Commentary. *Gut* 43: 601-601 [\[Full Text\]](#)

HASLER, W. L. (1999). THE EXPANDING SPECTRUM OF CLINICAL USES FOR **BOTULINUM** TOXIN: HEALING OF CHRONIC ANAL FISSURES. *Gastroenterology* 116: 221-223 [\[Full Text\]](#)

Münchau, A, Bhatia, K P (2000). Regular review: Uses of **botulinum** toxin injection in medicine today. *BMJ* 320: 161-165 [\[Full Text\]](#)

Carapeti, E A, Kamm, M A, Evans, B K, Phillips, R K S (1999). Topical diltiazem and bethanechol decrease anal sphincter pressure without side effects. *Gut* 45: 719-722 [\[Abstract\]](#) [\[Full Text\]](#)

Lysy, J, Israelit-Yatzkan, Y, Sestiery-Ittah, M, Weksler-Zangen, S, Keret, D, Goldin, E (2001).

Topical nitrates potentiate the effect of **botulinum**

ARTICLE
<ul style="list-style-type: none"> ► Return to Search Result ► Table of Contents ► Abstract of this article ► PDF of this article ► Related Letters to the Editor
Related editorials in the Journal: <ul style="list-style-type: none"> ► Madoff, R. D.
<ul style="list-style-type: none"> ► Find Similar Articles in the Journal ► Journal Watch Summary ► Journal Watch Summary
SERVICES
<ul style="list-style-type: none"> ► Add to Personal Archive ► Download to Citation Manager ► Alert me when this article is cited
MEDLINE
<ul style="list-style-type: none"> ► Related Articles in Medline
Articles in Medline by Author: <ul style="list-style-type: none"> ► Maria, G. ► Albanese, A.
<ul style="list-style-type: none"> ► Medline Citation
COLLECTIONS

toxin in the treatment of patients with refractory anal fissure. *Gut* 48: 221-224

[\[Abstract\]](#) [\[Full Text\]](#)

BHARDWAJ, R, VAIZEY, C J, BOULOS, P B, HOYLE, C H V (2000). Neuromyogenic properties of the internal anal sphincter: therapeutic rationale for anal fissures. *Gut* 46: 861-868 [\[Full Text\]](#)

Madoff, R. D. (1998). Pharmacologic Therapy for Anal Fissure. *N Engl J Med* 338: 257-259 [\[Full Text\]](#)

Perez-Miranda, M., Jimenez, J. M., Maria, G., Gui, D., Brisinda, G., Madoff, R. D. (1998). Treatment of Chronic Anal Fissure. *N Engl J Med* 338: 1698-1699 [\[Full Text\]](#)

Brisinda, G., Maria, G., Bentivoglio, A. R., Cassetta, E., Gui, D., Albanese, A. (1999). A Comparison of Injections of **Botulinum** Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure. *N Engl J Med* 341: 65-69 [\[Abstract\]](#) [\[Full Text\]](#)

Hallett, M. (1999). One Man's Poison -- Clinical Applications of **Botulinum** Toxin. *N Engl J Med* 341: 118-120 [\[Full Text\]](#)

McCallion, K, Gardiner, K R (2001). Progress in the understanding and treatment of chronic anal fissure. *Postgrad Med J* 77: 753-758 [\[Abstract\]](#) [\[Full Text\]](#)

► **Gastroenterology**
Related Chapters
► at Harrison's
Online

[HOME](#) | [SEARCH](#) | [CURRENT ISSUE](#) | [PAST ISSUES](#) |
[COLLECTIONS](#) | [HELP](#)

Comments and questions? Please [contact us](#).

The New England Journal of Medicine is owned, published, and
[copyrighted](#) © 2002 [Massachusetts Medical Society](#). All rights
reserved.

59/995,020

Regular review

Uses of botulinum toxin injection in medicine today

A Münchau, K P Bhatia

Botulinum neurotoxin is produced by the anaerobic bacterium *Clostridium botulinum*. It is the most poisonous biological substance known. Very small amounts of botulinum toxin can lead to botulism, a descending paralysis with prominent bulbar symptoms and often affecting the autonomic nervous system. Botulism can occur in two ways. It can result from infection with bacterial spores that produce and release the toxin in the body—as in enteric infectious botulism, when the bacteria grow in the intestine, and in wound botulism, when the wound becomes infected. Alternatively, botulism occurs after ingestion of the toxin (food borne botulism).¹

Botulism has been recognised since the early 19th century, and there was speculation about what caused the condition. In 1822 it was suggested that a “fatty acid” in sausages was the culprit,² and this led to the term botulism (*botulus* being the Latin word for sausage). In 1897, Van Ermengen related botulism to a bacterial toxin.³

The discovery that botulinum toxin blocks neuromuscular transmission⁴ and thereby causes weakness laid the foundation for its development as a therapeutic tool. In 1981, the ophthalmologist Alan Scott pioneered treatment with botulinum toxin when he used it to treat strabismus.⁵ He paved the way for clinical research in many specialties.

Methods

This review was prompted by an increasing number of publications on the therapeutic uses of botulinum neurotoxin. For the literature review we used standard textbooks⁶⁻⁹ and a Medline search for the years 1981 to 1999.

Mode of action

Strains of *Clostridium botulinum* produce seven antigenically distinct neurotoxins designated as serotypes A-G. All seven serotypes have a similar structure and molecular weight, consisting of a heavy (H) chain and a light (L) chain joined by a disulphide bond.¹⁰ They all interfere with neural transmission by blocking the release of acetylcholine (fig 1), which is the principal neurotransmitter at the neuromuscular junction. After synaptic transmission is blocked by botulinum toxin, the muscles become clinically weak and atrophic. The affected nerve terminals do not degenerate, but

Summary points

Botulinum toxin inhibits release of acetylcholine at the neuromuscular junction and in cholinergic sympathetic and parasympathetic neurones

Local injections of toxin weaken overactive muscles and control hypersecretion of glands supplied by cholinergic neurones

Botulinum toxin injections have an established role in some disorders of ocular motility

Botulinum toxin is the treatment of choice for focal dystonias such as torticollis and writer's cramp and for hemifacial spasm and may complement the management of spasticity

Local injections have also been shown to be beneficial in many other conditions including achalasia, chronic anal fissure, and hyperhidrosis

Treatment is usually well tolerated, the main side effect being weakness in adjacent muscles

the blockage of neurotransmitter release is irreversible. Function can be recovered by the sprouting of nerve terminals and formation of new synaptic contacts; this usually takes two to three months.

Rationale for treatment with botulinum neurotoxin


Botulinum toxin induces weakness of striated muscles by inhibiting transmission of alpha motor neurones at the neuromuscular junction. This has led to its use in conditions with muscular overactivity, such as dystonia. Transmission is also inhibited at gamma neurones in muscle spindles, which may alter reflex overactivity.¹¹

The toxin also inhibits release of acetylcholine in all parasympathetic and cholinergic postganglionic sympathetic neurones. This has fuelled interest in its use as a treatment for overactive smooth muscles (for example, in achalasia) or abnormal activity of glands (for example, hyperhidrosis).

University
Department of
Clinical Neurology,
Institute of
Neurology, London
WC1N 3BG
A Münchau
research fellow
K P Bhatia
senior lecturer

Correspondence to:
K P Bhatia
K.Bhatia@ion.ucl.ac.uk

BMJ 2000;320:161-5



Action of botulinum toxin at cholinergic nerve terminals. The heavy (H) chain of the toxin binds selectively and irreversibly to high affinity receptors at the presynaptic surface of cholinergic neurones, and the toxin-receptor complex is taken up into the cell by endocytosis. The disulphide bond between the two chains is cleaved (by an unknown mechanism), and the toxin escapes into the cytoplasm. The light (L) chains of the seven serotypes interact with different proteins (synaptosomal associated protein (SNAP) 25, vesicle associated membrane protein (VAMP) and syntaxin) in the nerve terminals to prevent fusion of acetylcholine vesicles with the cell membrane and thereby impede its release. (Adapted from Moore,⁶ with permission)

Preparations of botulinum neurotoxin

Serotype A is the only one commercially available for clinical use, although experience is emerging with serotypes B, C, and F.¹² Two preparations exist: Dysport, which is most widely used in the United Kingdom, and Botox, which is used in the United States and elsewhere. Unfortunately, there has been much confusion over the doses and units of potency of the two preparations. Although doses are quoted in mouse units (which is the amount of toxin that kills 50% of a group of 18-20 g female Swiss-Webster mice), implying some standardisation, Botox seems to be more potent. A recent study comparing the two preparations found that a unit of Botox is three times as potent as a unit of Dysport.¹³

Practical aspects of botulinum toxin injection treatment

Botulinum toxin has to be injected into affected muscles or glands. Doses have to be tailored according to the mode of use and individual patients. Generally, the effective dose depends on the mass of muscle being injected: the larger the muscle the higher the dose required. However, susceptibility to the toxin varies. Lower doses may be required in patients with pre-existing weakness and in women and lighter patients.

Overactive muscles are identified by muscular hypertrophy, stiffness, tenderness, and visible abnormal muscular activity. In addition, clinical observation of abnormal movements or postures may help identify an overactive muscle. Electromyography can also be useful—for example, in writer's cramp. Hollow Teflon coated needles are used to target toxin injections into affected muscles. In conditions with very localised

muscle overactivity in delicate places, such as strabismus, the injections are usually guided by electromyography.

The weakness induced by injection with botulinum toxin A usually lasts about three months. Patients will then need further injections at regular intervals, although the interval varies widely depending on the dose and individual susceptibility. Patients usually experience relief after each injection and then gradually deteriorate to a point where further injections are required. Response after the injections should be assessed both by using patient reported benefit in terms of pain relief and improvement of disability, and by objective measures on clinical examination.

Most patients treated with botulinum toxin require repeated injections over many years. Some patients who respond well initially develop tolerance to the injections. This can be caused by the development of neutralising antibodies to the toxin. Patients who receive higher individual doses or frequent booster injections seem to have a higher risk of developing antibodies. Injections should therefore be given at the lowest effective dose and as infrequently as possible.

Several types of antibody assay are available.¹⁴ The most widely used is the *in vivo* mouse neutralisation assay. In clinical trials patients resistant to botulinum A have benefited from injections with other serotypes, including B, C, and F. The duration of effect may differ widely with different serotypes—for example, the effect of botulinum F toxin lasts for only about two months in patients with torticollis, even when higher doses are used.¹⁵

Side effects

Injections with botulinum toxin are generally well tolerated. After injection the toxin diffuses into the muscles and other tissues. Its effect diminishes with increasing distance from the injection site, but spread to nearby muscles is possible, particularly when high volumes are injected. Patients receiving injections into the neck muscles for torticollis may therefore develop dysphagia because of diffusion of the toxin into the oropharynx. Distant effects shown by specialised electromyographic tests can also occur, but weakness of distant muscles or generalised weakness, possibly due to the toxin spreading in the blood, is very rare.^{16 17} However, botulinum toxin should be used only under close supervision in patients with disturbed neuromuscular transmission—for example, in myasthenia gravis or Lambert-Eaton myasthenic syndrome¹⁸ or during treatment with aminoglycosides. Other systemic side effects include an influenza-like illness and, rarely, brachial plexopathy, which may be immune mediated.¹⁹ No severe allergic reactions have been reported. Gallbladder dysfunction attributed to autonomic side effects of the toxin and a case of necrotising fasciitis in an 80 year old immunosuppressed woman with blepharospasm have been noted.^{20 21} Botulinum toxin is contraindicated in pregnancy and while breast feeding. Careful monitoring is important when the toxin is used in children as it might alter cell functions such as axonal growth.⁶

Indications for treatment

Over the past 15 years botulinum toxin has been shown to be useful in many conditions, especially strabismus and various movement disorders (box).

Disorders caused by overactivity of muscles for which treatment with botulinum toxin A is established

Ophthalmological disorders

Concomitant misalignment
Primary or secondary esotropia or exotropia
Nonconcomitant misalignment
Paralytic strabismus (III, IV, VI nerve palsy, internuclear ophthalmoplegia, skew deviation)
Duane's syndrome
Restrictive or myogenic strabismus

Movement disorders

Idiopathic focal dystonias
Craniocervical (torticollis and isolated head tremor, blepharospasm, oromandibular dystonia, lingual dystonia, laryngeal dystonia)
Other focal dystonias (writer's cramp, occupational cramps such as musician's cramp)
Tardive dystonia
Hemifacial spasm/post-facial nerve palsy synkinesis

Encouraging clinical reports have generated an abundance of ideas for other uses, but many of these observations are anecdotal. Nevertheless, its potency, relative safety, and the reversibility of its effects have made botulinum toxin an attractive option for some chronic conditions that respond only partially to medical treatment. Sometimes it can be used as an alternative to surgical intervention. In the following section we will focus on established indications of botulinum toxin.

Strabismus and other ocular motility disorders

The idea behind using botulinum toxin A in disorders of ocular motility is to shorten the non-injected antagonist muscle in order to align the visual axes.⁶ In patients with concomitant strabismus, who have compromised or absent binocular fusion, treatment is cosmetic as permanent ocular realignment cannot be expected. In secondary strabismus resulting from transient monocular vision loss (such as posttraumatic cataract), toxin injections can help to establish whether binocular cooperation is still present. If so, the patient would be a candidate for surgery to restore ocular function. Botulinum toxin has also proved useful when surgery has over or under corrected strabismus.²²

Paralytic strabismus is due to weakness of extraocular muscles—for example, the lateral rectus in abducens nerve palsy. Injections into the ipsilateral antagonist (medial rectus) can prevent contracture of this muscle. In restrictive causes of strabismus, for instance in dysthyroid eye disease, botulinum toxin can help to realign the eye before more definitive surgery. Complications include transient ptosis, subconjunctival haemorrhage, and transient vertical deviations of the globe.

Movement disorders

The effectiveness of botulinum toxin A in spasmodic torticollis was first shown in 1986,²³ and it is now the treatment of choice for this condition. Some improvement in pain relief, head position, and disability occurs in 90% of patients, and about three quarters achieve considerable improvement.²⁴ Injections are given into neck muscles, depending on the muscular activity and head position. Patients with severely restricted head movements usually respond less well to the injections.

The most common side effect (occurring in 5-9% of patients) is dysphagia, but this is usually transient.

Botulinum toxin is also the treatment of choice for primary blepharospasm (involuntary eye closure). Injections are given bilaterally into the overactive orbicularis oculi muscle. Possible side effects are partial ptosis or, rarely, double vision. A variant of blepharospasm in which eyelid opening is inhibited sometimes improves after injections into the pretarsal portion of the orbicularis oculi.²⁵

In oromandibular dystonia, injections are given into the masseter, temporalis, and internal pterygoid muscles for predominant jaw closing and into the digastric and external pterygoids for jaw opening spasms. Injections of the pterygoid muscles need electromyographic guidance. Symptoms are reduced in about 70% of patients, and treatment may prevent dental complications and temporomandibular joint dysfunction.⁶

In a large series of patients with laryngeal dystonia, treatment with botulinum toxin A resulted in normal or

Examples of overactive muscle conditions for which treatment with botulinum toxin A has been tried

Ophthalmic disorders

Disorders of ocular motility (nystagmus and oscillopsia)
Thyroid disease (upper eyelid retraction, glabellar furrowing)
Therapeutic ptosis for corneal protection

Movement disorders

Secondary dystonia
Tic disorders (simple tics, Tourette's syndrome, dystonic tics)
Tremor (essential, primary writing, palatal, cerebellar)
Painful spinal myoclonus
Parkinson's disease (freezing of gait, off period dystonia, severe constipation)
Cephalic tetanus, stiff man syndrome, neuromyotonia
Muscle stiffness, cramps, spasms

Spasticity

Multiple sclerosis
Stroke
Traumatic brain injury
Cerebral palsy
Spinal cord injury

Neuromuscular disorders

Myokymia
Neurogenic tibialis anterior hypertrophy with myalgia
Benign cramp-fasciculation syndrome

Pain

Headache (tension type, migraine, cervicogenic)
Backache (neck, lower back)
Myofascial pain
Tennis elbow

Ear, nose, and throat disorders

Oromandibular disorders (bruxism, Masseter hypertrophy, temporomandibular joint dysfunction)
Pharyngeal disorders (cricopharyngeal dysphagia, closure of larynx in chronic aspiration)
Laryngeal disorders (vocal fold granuloma, ventricular dysphonia, mutational dysphonia)
Stuttering with glottal blocks

Disorders of pelvic floor

Anismus
Vaginismus
Anal fissures
Detrusor-sphincter dyssynergia

Cosmetic applications

Wrinkles, frown lines
Rejuvenation of ageing neck

Other disorders for which botulinum toxin A has been tried**Overactivity of smooth muscles**

Oesophageal disorders (achalasia, diffuse oesophageal spasm, oesophageal diverticulosis)
Sustained sphincter of Oddi hypertension
Gastric pyloric spasms

Hypersecretion of glands supplied by cholinergic sympathetic or parasympathetic neurones

Ptyalism
Increased tearing
Hyperhidrosis (axillary, palmar, gustatory)
Intrinsic rhinitis

near normal voice in patients with adductor type (strained or strangled voice) and considerable benefit in patients with abductor type (breathy, whispery voice).²⁶ Injections can be carried out by indirect laryngoscopy or percutaneously with electromyographic guidance. Adverse symptoms are transient hypophonia, hoarseness, and mild aspiration of fluids and sometimes stridor.

Botulinum toxin injections have been shown to provide effective relief for writer's cramp, with pain being generally more improved than motor function.²⁷ The muscles to be injected are usually identified on clinical grounds, but electromyography is used to inject the toxin accurately. Improvement of function is almost invariably associated with some weakness. Other occupational cramps, such as musician's cramp, respond less well to injections as they require very sophisticated neuromuscular performance.

Botulinum toxin is also an effective treatment for hemifacial spasm.²⁸ Before treatment patients should have magnetic resonance imaging of the brain to rule out structural lesions in the cerebello-pontine angle. Nearly all injected patients improve, and the effect can last longer than in patients with dystonia (about five months), possibly because of pre-existing facial weakness. Treatment can be individualised by injecting only those muscles whose contractions are most disturbing to the patient—for example, the orbicularis oculi for involuntary eye closure. Excessive facial weakness is the most common side effect.

Botulinum toxin has been used in several other movement disorders, including tics and various tremor disorders, although the response is usually less than in dystonia, particularly in tremor patients.²⁹

Spasticity

Botulinum toxin has been evaluated in various spastic disorders.³⁰ It was shown to improve gait pattern in patients with cerebral palsy with progressive dynamic equinovarus or equinovagis foot deformities. Treatment of children with cerebral palsy during the key early years when functional skills in walking are being developed improves the outcome and may help to avoid surgery for contracture and bony torsion.³¹ In multiple sclerosis the toxin can relieve contractions of thigh adductors that interfere with sitting, positioning, cleaning, and urethral catheterisation. It can also reduce muscle tone and increase range of movement in upper extremity spasticity or in spastic foot drop after a stroke. Whether this translates into functional improvement has yet to be substantiated.³²

Other indications

Botulinum toxin has been tried in numerous other conditions (box). The list of possible new indications is rapidly expanding. It seems to be a promising alternative to sphincterotomy in patients with chronic anal fissures³³ and is effective in achalasia.³⁴ Some autonomic disorders resulting in hypersecretion of glands like excessive palmar hyperhidrosis, ptyalism, or gustatory sweating, which often occurs after surgery to the parotid gland, respond well to botulinum toxin.³⁵⁻³⁷ Surprisingly, the response seems to last much longer than in conditions caused by overactivity of striated or smooth muscles.³⁶

Although botulinum toxin has been tried in many conditions, in the United Kingdom it is currently licensed only for blepharospasm, hemifacial spasm, and spasmodic torticollis. In medical practice today botulinum toxin A is probably mostly used for treatment of focal dystonias, hemifacial spasm, and spasticity. Further clinical experience is needed before definitive treatment recommendations in other conditions are made.

We thank Professor Niall P Quinn and Dr Cathy Chuang for critical review of the manuscript.

Funding: AM was supported by the Ernst Jung-Stiftung für Wissenschaft und Forschung in Hamburg, Germany.

Competing interests: KPB and AM have been supported by Ipsen, the manufacturer of Dysport, to attend an international symposium.

- Cherington M. Clinical spectrum of botulism. *Muscle Nerve* 1998;21: 701-10.
- Kerner J. Vergiftung durch verdorbene Würste. *Tübinger Blätt Naturwissenschaften Arzneikunde* 1817;3:1-25.
- Van Ermengem E. Über einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. *Z Hyg Infektionskrankh* 1897;26:1-56.
- Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuromuscular junction. *J Physiol* 1949;109:10-24.
- Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. *Trans Am Ophthalmol Soc* 1981;79:734-70.
- Moore P, ed. *Handbook of botulinum toxin*. Oxford: Blackwell Science, 1995.
- Jankovic J, Hallett M, eds. *Therapy with botulinum toxin*. New York: Marcel Dekker, 1994.
- Fahn S, Marsden CD, DeLong MR, eds. *Advances in neurology. Dystonia*. Philadelphia: Lippincott-Raven, 1998.
- Dressler D. *Botulinum Toxin Therapie*. Stuttgart: Thieme Verlag, 1998.
- Dolly JO. Therapeutic and research exploitation of botulinum neurotoxins. *Eur J Neurol* 1997;4(suppl2):S5-10.
- Priori A, Berardelli A, Mercuri B, Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia: changes in reciprocal inhibition between forearm muscles. *Brain* 1995;118:801-7.
- Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. *Muscle Nerve* 1997;20(suppl 6):S129-45.
- Odergren T, Hjalason H, Kaakkola S, Söders G, Hanks J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. *J Neurol Neurosurg Psychiatry* 1998;64:6-12.
- Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. *Muscle Nerve* 1997;20(suppl 6):S146-68.
- Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. *J Neurol Neurosurg Psychiatry* 1998;64:577-80.
- Bakheit AMO, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases (letter). *J Neurol Neurosurg Psychiatry* 1997;62:198.
- Bhatia KP, Münchau A, Thompson PD, Houser M, Chauhan VS, Hutchinson M, et al. Generalised muscular weakness following botulinum toxin injections for dystonia: a report of 3 cases. *J Neurol Neurosurg Psychiatry* 1999;67:90-3.
- Erbguth F, Claus D, Engelhardt A, Dressler D. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. *J Neurol Neurosurg Psychiatry* 1993;56:1235-6.
- Glanzman RL, Gelb DJ, Drury I, Bromberg MB, Truong DD. Brachial plexopathy after botulinum toxin injections. *Neurology* 1990;40:1143.
- Schneider P, Brichta A, Schmied M, Auff E. Gallbladder dysfunction induced by botulinum A toxin. *Lancet* 1993;342:811-2.
- Latimer PR, Hodgkins PR, Vakalis, Butler RE, Evans AR, Zaki GA. Necrotising fasciitis as a complication of botulinum toxin treatment. *Eye* 1998;12:51-3.
- Scott AB, Magoon EH, McNeer KW, Stager DR. Botulinum treatment of childhood strabismus. *Ophthalmology* 1990;97:1434-8.
- Tsui JKC, Eisen A, Stoeddl AJ, Calne S. Double-blind study of botulinum toxin in spasmodic torticollis. *Lancet* 1986;ii:245-7.

- 24 Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, et al. Botulinum toxin treatment of spasmodic torticollis. *J R Soc Med* 1992;85:524-9.
- 25 Lepore V, Defazio G, Acquistapance P, Helpignano C, Powes L, Lambert P, et al. Botulinum A toxin for the so-called apraxia of lid opening. *Mov Disord* 1995;10:525-6.
- 26 Brin MF, Blitzer A, Steward C. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. In: Fahn S, Marsden CD, DeLong MR, eds. *Advances in neurology. Dystonia*. Philadelphia: Lippincott-Raven, 1998:237-52.
- 27 Tsui JKC, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer's cramp: a double-blind study. *Neurology* 1993;43:183-5.
- 28 Jitipimolnart S, Tiarnkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. *J Neurol Neurosurg Psychiatry* 1998;64:751-7.
- 29 Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. *Mov Disord* 1994;9:601-9.
- 30 Simpson DM. Clinical trials of botulinum toxin in the treatment of spasticity. *Muscle Nerve* 1997;20(suppl 6):S169-75.
- 31 Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. *Eur J Neurol* 1997;4(suppl 2):S15-22.
- 32 Sheehan GL. The treatment of spasticity with botulinum toxin. In: Sheehan GL, Barnes MP, eds. *Spasticity rehabilitation*. London: Churchill Communications, 1998:109-26.
- 33 Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. *N Engl J Med* 1998;338:217-20.
- 34 Cuillier C, Ducrotte P, Zerbib F, Metman EH, de Looze D, Guillemot F, et al. Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. *Gut* 1997;41:87-92.
- 35 Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. *J Am Acad Dermatol* 1998;38:227-9.
- 36 Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. *Ann Neurol* 1997;42:973-5.
- 37 Bhatia KP, Münchau A, Brown P. Botulinum toxin is a useful treatment in extensive drooling of saliva. *J Neurol Neurosurg Psychiatry* 1999;67:697.

(Accepted 16 August 1999)

Evidence based case report

Asymptomatic haematuria ... in the doctor

Chris Del Mar

The patient was waiting in the consulting room; everything was nearly ready. The occasion was the examination in general practice for fifth year medical students. We run an objective structured clinical examination. For this part, the student had to measure the patient's blood pressure (the "patient" was actually someone recruited from our general practice), test his urine using a dipstick, and report to the examiner within the five minutes between bells. Just one thing was missing—the midstream sample of normal urine for testing. Because I did not want to disturb the volunteer patient, I collected it from myself. I measured the patient's blood pressure again (this had to be done after every 10th student)—it was stable. And I tested the urine to check it was normal—it was not.

For the next two hours, students either told me (or, in the case of those less skilled at this technique, did not tell me) that there was a trace of blood in the urine. This was not a problem as far as the examination was concerned because the marking was not affected by the test result. But it was a problem for me. What should I do? I tested my urine again a week later, and when I found it was still positive I sent a specimen to the laboratory. The report stated that urine culture was negative but confirmed the presence of normal red cells (30/ml).

Conventional medical teaching had taught me that bleeding must come from somewhere. The model that sprang to mind first is summarised in the table. I then checked with a textbook of surgery.¹ I had forgotten tuberculosis and schistosomiasis as causes of haematuria. A textbook of medicine² suggested further assessments, including checking my blood relatives for urine abnormality and carrying out haemoglobin electrophoresis and 24 hour urinary estimations of urate and calcium excretion. If all these investigations were negative, intravenous urography, cystoscopy, and renal computed tomography were proposed, with indefinite regular follow up thereafter. The essential feature of this model is that identifying the lesion anatomically or physiologically is the key to managing the problem. Early diagnosis of some of the serious causes of

haematuria such as transitional cell carcinoma might affect the outcome favourably by enabling treatment to be given. With other causes such as minimal change glomerulonephritis, early diagnosis is unlikely to affect mortality or morbidity.

I consulted my general practice colleague. His approach was similar. He ensured that I had checked my urine microscopy and culture to establish whether the blood was haemolysed or not, and he measured my blood pressure. He wondered whether my bicycle riding might be the cause, and suggested I recheck the urine after a month or two. If test results were still positive, it looked as if the cascade of likely events would include ultrasonography, urine samples for malignant cells, and then probably referral to a urologist for consideration of cystoscopy and intravenous urography.

"We probably won't find any cause for it," he said. I think this was to reassure me. I had time to think about adopting an evidence based approach.

Formulating the question

The most difficult part of adopting evidence in practice is formulating the question. This involves quite a different way in thinking—away from "patho-anatomical-physiological" questions towards empirical ones. What is the chance of having a serious condition with asymptomatic haematuria? What sort of study did I want? Ideally, it would be huge study of general

Centre for General Practice, University of Queensland, The University General Practice, Inala, Queensland 4077, Australia

Chris Del Mar
professor

c.delmar@mailbox.uq.edu.au

BMJ 2000;320:165-6

Causes and management of haematuria

Site of bleeding	Disease	Management
Generalised	Bleeding diathesis	Check bleeding and coagulation profiles; treat accordingly
Lower renal tract	Prostate hypertrophy or cancer; urethral inflammation; bladder lesion or cancer	Cystoscopy; treat accordingly
Ureteric lesions	Transitional cell carcinoma; ureteric calculi	Ultrasonography or intravenous urography; treat accordingly
Renal lesions	Cancer; calculi; vascular abnormalities; reflux nephropathy; glomerular lesions	Check blood pressure; ultrasonography or intravenous urography; treat accordingly